MarketCap
Facebook
X
Telegram
AbbVie Long Term Debt Current | ABBV
Annual Long Term Debt Current AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 194 M | 178 M | 166 M | 166 M | 178 M | 175 M | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 194 M | 166 M | 176 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
PMV Pharmaceuticals
PMVP
|
403 K | $ 1.25 | 2.87 % | $ 65.7 M |  USA |
 |
Olema Pharmaceuticals
OLMA
|
1.12 M | $ 8.16 | 12.24 % | $ 710 M | USA |
 |
Kymera Therapeutics
KYMR
|
11.9 M | $ 135.02 | -1.19 % | $ 11.4 B | USA |
 |
Oragenics
OGEN
|
9.81 K | $ 0.35 | 1.4 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
1.43 M | $ 2.77 | -1.07 % | $ 361 M | USA |
 |
Passage Bio
PASG
|
1.15 M | $ 3.91 | 3.44 % | $ 12.5 M | USA |
 |
Vaxcyte
PCVX
|
6.12 M | $ 68.44 | 3.13 % | $ 9.31 B | USA |
 |
Relay Therapeutics
RLAY
|
3.76 M | $ 19.87 | -0.35 % | $ 3.41 B | USA |
 |
Precigen
PGEN
|
1.14 M | $ 4.75 | 4.98 % | $ 1.49 B | USA |
 |
Avidity Biosciences
RNA
|
3.94 M | $ 7.97 | -3.22 % | $ 1.1 B | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
35 K | $ 0.81 | -0.07 % | $ 4.85 M | USA |
 |
Spero Therapeutics
SPRO
|
1.96 M | $ 1.02 | 1.49 % | $ 57.1 M | USA |
 |
Praxis Precision Medicines
PRAX
|
110 K | $ 346.47 | 2.63 % | $ 7.8 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
2.74 M | $ 3.8 | 1.06 % | $ 292 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
1.54 M | $ 1.26 | -3.82 % | $ 133 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
2.82 M | $ 6.66 | 0.68 % | $ 1.25 B | USA |
 |
PolyPid Ltd.
PYPD
|
1.16 M | $ 6.56 | 3.96 % | $ 107 M |  Israel |
 |
Outlook Therapeutics
OTLK
|
58.9 K | $ 0.48 | 4.34 % | $ 16.7 M | USA |
 |
uniQure N.V.
QURE
|
3.86 M | $ 24.64 | 8.5 % | $ 1.42 B | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
12 M | $ 16.7 | 3.44 % | $ 1.65 B | USA |
 |
Sarepta Therapeutics
SRPT
|
11.2 M | $ 16.67 | 1.4 % | $ 1.67 B | USA |
 |
REGENXBIO
RGNX
|
8.29 M | $ 8.57 | 11.38 % | $ 442 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
614 K | $ 44.17 | 0.58 % | $ 794 M | USA |
 |
SELLAS Life Sciences Group
SLS
|
544 K | $ 8.41 | 0.5 % | $ 917 M | USA |
 |
Celsion Corporation
CLSN
|
406 K | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
21.9 M | - | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
107 K | $ 1.7 | 0.3 % | $ 66.7 M | USA |
 |
CureVac N.V.
CVAC
|
5.32 M | - | - | $ 867 M |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
8.5 M | - | - | $ 4.9 B |  Britain |
 |
Rezolute
RZLT
|
658 K | $ 4.09 | 1.74 % | $ 425 M | USA |
 |
Tiziana Life Sciences PLC
TLSA
|
106 K | $ 0.62 | 1.33 % | $ 66.1 M | Britain |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
539 K | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
784 K | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
2.58 M | $ 1.61 | -0.31 % | $ 88.9 M | USA |
 |
Gracell Biotechnologies
GRCL
|
17.5 M | - | - | $ 3.37 B | China |
 |
Shattuck Labs
STTK
|
837 K | $ 5.04 | 3.61 % | $ 351 M | USA |
|
Silence Therapeutics plc
SLN
|
179 K | $ 19.78 | -0.05 % | $ 2.8 B | Britain |
 |
Stoke Therapeutics
STOK
|
3.01 M | $ 27.75 | 1.98 % | $ 1.64 B | USA |
 |
Sutro Biopharma
STRO
|
7.78 M | $ 10.25 | 0.79 % | $ 87.1 M | USA |
 |
Soligenix
SNGX
|
114 K | $ 0.32 | 0.37 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
288 M | $ 43.19 | 1.85 % | $ 49.5 B | Israel |